How to buy Amgen (AMGN) shares in the UK

Learn how to easily invest in Amgen shares.

Amgen Inc
NASDAQ: AMGN - USD
$245.37
+ $2.28 ( + 0.94%)
DRUG MANUFACTURERS-GENERAL

Amgen Inc (AMGN) is a publicly traded drug manufacturers-general business based in the US. It opened the day at $244 after a previous close of $243.09. During the day the price has varied from a low of $242.875 to a high of $246. The latest price was $245.37 (25 minute delay). Amgen is listed on the NASDAQ and employs 24,200 staff. All prices are listed in US Dollars.

How to buy shares in Amgen

  1. Choose a platform. If you're a beginner, our share-dealing table below can help you choose.
  2. Open your account. You'll need your ID, bank details and national insurance number.
  3. Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
  4. Search the platform for stock code: AMGN in this case.
  5. Research Amgen shares. The platform should provide the latest information available.
  6. Buy your Amgen shares. It's that simple.
The whole process can take as little as 15 minutes. You'll need a smartphone or computer, an internet connection, your passport or driving licence and a means of payment.

Fees for buying 5x Amgen shares with popular platforms

Both exchange rates and share prices fluctuate in real time, so the costs presented here should be considered as a guide only. They do not incorporate stamp duty. Always refer to the platform itself for availability and pricing – which may differ from our information.

Platform Platform fee Min. initial deposit Trading fee estimate
eToro Free Stocks logo £0 $10 £5.00
£1,004.88 total
Capital at risk
Freetrade logo £0 £1 £4.50
£1,004.38 total
Capital at risk
Fineco logo £0 No minimum £10.00
£1,009.88 total
Capital at risk
IG Share Dealing logo £0 £250 £13.19
£1,013.07 total
Capital at risk
Hargreaves Lansdown Fund and Share Account logo £0 £1 £21.95
£1,021.83 total
Capital at risk
Degiro Share Dealing logo £0 £0.01 £1.00
£1,000.88 total
Capital at risk
interactive investor Trading Account logo £9.99 per month No minimum £22.99
£1,022.87 total
Capital at risk
Stake logo £0 £50 £5.00
£1,004.88 total
Capital at risk
Halifax Share Dealing Account logo £36 per year £20 £22.00
£1,021.88 total
Capital at risk

Full comparison of share dealing platforms

Amgen share price (NASDAQ:AMGN)

Use our graph to track the performance of AMGN stocks over time.

Is it a good time to buy Amgen stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Promoted
eToro Free Stocks

Invest in Amgen shares with 0% commission

  • Start investing from as little as $10
  • Pay no stamp duty on UK shares
  • Join 25 million users who trust their investments with eToro
Other fees apply. Capital at risk

All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.

Is Amgen under- or over-valued?

Valuing a stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of overall performance. However, analysts commonly use some key metrics to help gauge value.

P/E ratio

Amgen's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 23x. In other words, Amgen shares trade at around 23x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

However, Amgen's P/E ratio is best considered in relation to those of others within the drug manufacturers-general industry or those of similar companies.

PEG ratio

Amgen's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.4042. A PEG ratio over 1 can be interpreted as meaning shares are overvalued at the current rate of growth, or may anticipate an acceleration in growth.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Amgen's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

However, it's sensible to consider Amgen's PEG ratio in relation to those of similar companies.

EBITDA

Amgen's EBITDA (earnings before interest, taxes, depreciation and amortisation) is a whopping $12.9 billion (£10.5 billion).

The EBITDA is a measure of a Amgen's overall financial performance and is widely used to measure a its profitability.

To put that into context you can compare it against similar companies.

Environmental, social and governance track record

Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Amgen.

Total ESG risk score

Amgen's total ESG risk: 20.95

Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Amgen's overall score of 20.95 (as at 01/01/2019) is pretty good – landing it in it in the 24th percentile of companies rated in the same sector.

ESG scores are increasingly used to estimate the level of risk a company like Amgen is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).

To gain some more context, you can compare Amgen's total ESG risk score against those of similar companies.

Environmental score

Amgen's environmental score: 1.53/100

Amgen's environmental score of 1.53 puts it squarely in the 3rd percentile of companies rated in the same sector. This could suggest that Amgen is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.

Social score

Amgen's social score: 15.13/100

Amgen's social score of 15.13 puts it squarely in the 3rd percentile of companies rated in the same sector. This could suggest that Amgen is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.

Governance score

Amgen's governance score: 5.8/100

Amgen's governance score puts it squarely in the 3rd percentile of companies rated in the same sector. That could suggest that Amgen is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.

Controversy score

Amgen's controversy score: 2/5

ESG scores also evaluate any incidences of controversy that a company has been involved in. A high-profile company, Amgen scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that Amgen has, for the most part, managed to keep its nose clean.

Wondering how that compares? Below are the controversy scores of similar companies.

Environmental, social, and governance (ESG) summary

Amgen Inc was last rated for ESG on: 2019-01-01.

Total ESG score 20.95
Total ESG percentile 23.7
Environmental score 1.53
Environmental score percentile 3
Social score 15.13
Social score percentile 3
Governance score 5.8
Governance score percentile 3
Level of controversy 2

Amgen shares at a glance

Information last updated 2022-06-24.
Open$244
High$246
Low$242.875
Close$245.37
Previous close$243.09
Change$2.28
Change %0.9379%
Volume4,088,144
Information last updated 2022-06-21.
52-week range$195.3815 - $257.97
50-day moving average$245.3334
200-day moving average$226.6958
Wall St. target price$250.03
PE ratio23.1937
Dividend yield$7.22 (3.31%)
Earnings per share (TTM)$10.12

Amgen share dividends

3.3%

Dividend yield: 3.31% of stock value

3.3%

Forward annual dividend yield: 3.31% of stock value

41.9%

Dividend payout ratio: 41.9% of net profits

Amgen has recently paid out dividends equivalent to 3.31% of its share value annually.

Amgen has paid out, on average, around 41.9% of recent net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 3.31% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), shareholders could enjoy a 3.31% return on their shares, in the form of dividend payments. In Amgen's case, that would currently equate to about $7.22 per share.

While Amgen's payout ratio might seem fairly standard, it's worth remembering that it may be investing much of the rest of its net profits in future growth.

Amgen's most recent dividend payout was on 8 June 2022. The latest dividend was paid out to all shareholders who bought their shares by 16 May 2022 (the "ex-dividend date").

Amgen's dividend yield is perhaps best considered in relation to those of similar companies.

Share price volatility

Over the last 12 months, Amgen's shares have ranged in value from as little as $195.3815 up to $257.97. A popular way to gauge a stock's volatility is its "beta".

AMGN.US volatility(beta: 0.57)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Amgen's is 0.5726. This would suggest that Amgen's shares are less volatile than average (for this exchange).

To put Amgen's beta into context you can compare it against those of similar companies.

Amgen overview

In April 2021, Amgen acquired Five Prime Therapeutics, a clinical stage biotechnology company.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site